These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 19660879)

  • 21. Improve dosimetric outcome in stage III non-small-cell lung cancer treatment using spot-scanning proton arc (SPArc) therapy.
    Li X; Kabolizadeh P; Yan D; Qin A; Zhou J; Hong Y; Guerrero T; Grills I; Stevens C; Ding X
    Radiat Oncol; 2018 Feb; 13(1):35. PubMed ID: 29486782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer.
    Murshed H; Liu HH; Liao Z; Barker JL; Wang X; Tucker SL; Chandra A; Guerrero T; Stevens C; Chang JY; Jeter M; Cox JD; Komaki R; Mohan R
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1258-67. PubMed ID: 15001271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dosimetric comparison of intensity modulated radiotherapy and intensity modulated proton therapy in the treatment of recurrent nasopharyngeal carcinoma.
    Hung HM; Chan OCM; Mak CH; Hung WM; Ng WT; Lee MCH
    Med Dosim; 2022 Spring; 47(1):14-19. PubMed ID: 34470708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Four-dimensional computed tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esophageal cancer.
    Zhang X; Zhao KL; Guerrero TM; McGuire SE; Yaremko B; Komaki R; Cox JD; Hui Z; Li Y; Newhauser WD; Mohan R; Liao Z
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):278-87. PubMed ID: 18722278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Limited Impact of Setup and Range Uncertainties, Breathing Motion, and Interplay Effects in Robustly Optimized Intensity Modulated Proton Therapy for Stage III Non-small Cell Lung Cancer.
    Inoue T; Widder J; van Dijk LV; Takegawa H; Koizumi M; Takashina M; Usui K; Kurokawa C; Sugimoto S; Saito AI; Sasai K; Van't Veld AA; Langendijk JA; Korevaar EW
    Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):661-9. PubMed ID: 27681763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of photon volumetric modulated arc therapy, intensity-modulated proton therapy, and intensity-modulated carbon ion therapy for delivery of hypo-fractionated thoracic radiotherapy.
    Chi A; Lin LC; Wen S; Yan H; Hsi WC
    Radiat Oncol; 2017 Aug; 12(1):132. PubMed ID: 28810881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intensity-modulated proton and carbon-ion radiotherapy using a fixed-beam system for locally advanced lung cancer: dosimetric comparison with x-ray radiotherapy and normal tissue complication probability (NTCP) evaluation.
    Ming X; Mao J; Ma N; Chen J; Wang W; Sheng Y; Wu K
    Phys Med Biol; 2024 Jan; 69(1):. PubMed ID: 38064747
    [No Abstract]   [Full Text] [Related]  

  • 28. An isotoxic planning comparison study for stage II-III non-small cell lung cancer: is intensity-modulated radiotherapy the answer?
    Warren M; Webster G; Ryder D; Rowbottom C; Faivre-Finn C
    Clin Oncol (R Coll Radiol); 2014 Aug; 26(8):461-7. PubMed ID: 24793504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intensity-modulated proton therapy for elective nodal irradiation and involved-field radiation in the definitive treatment of locally advanced non-small-cell lung cancer: a dosimetric study.
    Kesarwala AH; Ko CJ; Ning H; Xanthopoulos E; Haglund KE; O'Meara WP; Simone CB; Rengan R
    Clin Lung Cancer; 2015 May; 16(3):237-44. PubMed ID: 25604729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Technical Note: Treatment planning system (TPS) approximations matter - comparing intensity-modulated proton therapy (IMPT) plan quality and robustness between a commercial and an in-house developed TPS for nonsmall cell lung cancer (NSCLC).
    Liu C; Yu NY; Shan J; Bhangoo RS; Daniels TB; Chiang JS; Ding X; Lara P; Patrick CL; Archuleta JP; DeWees T; Hu Y; Schild SE; Bues M; Sio TT; Liu W
    Med Phys; 2019 Nov; 46(11):4755-4762. PubMed ID: 31498885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Individualized dose prescription for hypofractionation in advanced non-small-cell lung cancer radiotherapy: an in silico trial.
    Hoffmann AL; Troost EG; Huizenga H; Kaanders JH; Bussink J
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1596-602. PubMed ID: 22245206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of heart and coronary artery doses associated with intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for distal esophageal cancer.
    Kole TP; Aghayere O; Kwah J; Yorke ED; Goodman KA
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1580-6. PubMed ID: 22284687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multi-criteria optimization achieves superior normal tissue sparing in a planning study of intensity-modulated radiation therapy for RTOG 1308-eligible non-small cell lung cancer patients.
    Kamran SC; Mueller BS; Paetzold P; Dunlap J; Niemierko A; Bortfeld T; Willers H; Craft D
    Radiother Oncol; 2016 Mar; 118(3):515-20. PubMed ID: 26830694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fully automated VMAT treatment planning for advanced-stage NSCLC patients.
    Della Gala G; Dirkx MLP; Hoekstra N; Fransen D; Lanconelli N; van de Pol M; Heijmen BJM; Petit SF
    Strahlenther Onkol; 2017 May; 193(5):402-409. PubMed ID: 28314877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison.
    Trofimov A; Nguyen PL; Coen JJ; Doppke KP; Schneider RJ; Adams JA; Bortfeld TR; Zietman AL; Delaney TF; Shipley WU
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):444-53. PubMed ID: 17513063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 4π noncoplanar stereotactic body radiation therapy for centrally located or larger lung tumors.
    Dong P; Lee P; Ruan D; Long T; Romeijn E; Low DA; Kupelian P; Abraham J; Yang Y; Sheng K
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):407-13. PubMed ID: 23523322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiopulmonary Toxicity Following Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Radiation Therapy (IMRT) for Stage III Non-Small Cell Lung Cancer.
    Yu NY; DeWees TA; Voss MM; Breen WG; Chiang JS; Ding JX; Daniels TB; Owen D; Olivier KR; Garces YI; Park SS; Sarkaria JN; Yang P; Savvides PS; Ernani V; Liu W; Schild SE; Merrell KW; Sio TT
    Clin Lung Cancer; 2022 Dec; 23(8):e526-e535. PubMed ID: 36104272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiac Dose in Locally Advanced Lung Cancer: Results From a Statewide Consortium.
    Dess RT; Sun Y; Muenz DG; Paximadis PA; Dominello MM; Grills IS; Kestin LL; Movsas B; Masi KJ; Matuszak MM; Radawski JD; Moran JM; Pierce LJ; Hayman JA; Schipper MJ; Jolly S;
    Pract Radiat Oncol; 2020; 10(1):e27-e36. PubMed ID: 31382026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is clinical target volume necessary for locally advanced non-small cell lung cancer treated with 4D-CT intensity-modulated radiation therapy.
    Ding W; Xu T; Xiang H; Liang J; Liang W; Xiang N; Zhao J; Li G; Song Z
    BMC Cancer; 2024 Sep; 24(1):1198. PubMed ID: 39334061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dosimetric comparison between 2-dimensional radiation therapy and intensity modulated radiation therapy in treatment of advanced T-stage nasopharyngeal carcinoma: to treat less or more in the planning organ-at-risk volume of the brainstem and spinal cord.
    Chau RM; Teo PM; Kam MK; Leung SF; Cheung KY; Chan AT
    Med Dosim; 2007; 32(4):263-70. PubMed ID: 17980826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.